報價延遲最少15分鐘:2025/07/03 06:21 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
48.64 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.43/2.70
|
|
企業價值
11.78B
|
| 資產負債 |
|
每股賬面淨值
15.74
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
1.97B
|
|
每股收益
9.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/03 06:21 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%). |